BALAXI PHARMACEUTICALS
Quarterly Results Analysis [Mar2025]
BALAXI PHARMACEUTICALS Quarterly Results
Consolidated | Mar2025 Audited |
Dec2024 UnAudited |
Sep2024 UnAudited |
Jun2024 UnAudited |
Mar2024 Audited |
Dec2023 Audited |
Sep2023 Audited |
Jun2023 UnAudited |
---|---|---|---|---|---|---|---|---|
Revenues | ₹76 Cr | ₹73 Cr | ₹77 Cr | ₹66 Cr | ₹60 Cr | ₹61 Cr | ₹55 Cr | ₹66 Cr |
Expenses | ₹64 Cr | ₹69 Cr | ₹67 Cr | ₹56 Cr | ₹46 Cr | ₹47 Cr | ₹44 Cr | ₹57 Cr |
Operating Income | ₹13 Cr | ₹4 Cr | ₹11 Cr | ₹10 Cr | ₹13 Cr | ₹14 Cr | ₹11 Cr | ₹9 Cr |
Other Income | ₹-2 Cr | ₹4 Cr | ₹-4 Cr | ₹-2 Cr | ₹-2 Cr | ₹0 Cr | ₹0 Cr | ₹-1 Cr |
Interest | ₹1 Cr | ₹1 Cr | ₹0 Cr | ₹0 Cr | ₹1 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
Depreciation | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹1 Cr | ₹0 Cr | ₹1 Cr | ₹0 Cr |
Profit Before Tax | ₹10 Cr | ₹6 Cr | ₹6 Cr | ₹7 Cr | ₹11 Cr | ₹14 Cr | ₹16 Cr | ₹-39 Cr |
Profit After Tax | ₹9 Cr | ₹5 Cr | ₹5 Cr | ₹6 Cr | ₹11 Cr | ₹14 Cr | ₹14 Cr | ₹-41 Cr |
EPS | ₹1.56 | ₹0.97 | ₹0.83 | ₹1.17 | ₹10.03 | ₹2.66 | ₹2.82 | ₹-8.08 |
Industry Peers & Returns | 1W | 1M | 1Y |
BALAXI PHARMACEUTICALS | 6.8% | -2.7% | -48.4% |
ADANI ENTERPRISES | 3.1% | 5.7% | -17.9% |
REDINGTON | 3.5% | 5.1% | 42.7% |
MMTC | -4.6% | 27.7% | 6.3% |
HONASA CONSUMER | 0.2% | 23.5% | -27.5% |
LLOYDS ENTERPRISES | 12.7% | 42.3% | 121.7% |
ENTERO HEALTHCARE SOLUTIONS | -1.4% | -17.2% | 15.8% |
OPTIEMUS INFRACOM | 1.1% | 10.4% | 140% |
POLO QUEEN INDUSTRIAL & FINTECH | 0.3% | -12.2% | 38.8% |
BALAXI PHARMACEUTICALS Quarterly Revenues
Revenues | |
---|---|
Q-o-Q | 4.06 % |
Y-o-Y | 27.46 % |
Quarters | Revenues | % Change | |
---|---|---|---|
Mar2025 | ₹76 Cr | 4.06 | |
Dec2024 | ₹73 Cr | -5.29 | |
Sep2024 | ₹77 Cr | 17.92 | |
Jun2024 | ₹66 Cr | 9.68 | |
Mar2024 | ₹60 Cr | -1.57 | |
Dec2023 | ₹61 Cr | 11.08 | |
Sep2023 | ₹55 Cr | -17.03 | |
Jun2023 | ₹66 Cr | - |
BALAXI PHARMACEUTICALS Quarterly Operating Profit
Operating Profit | |
---|---|
Q-o-Q | 214.85 % |
Y-o-Y | -6.78 % |
Quarters | Operating Profit | % Change | |
---|---|---|---|
Mar2025 | ₹13 Cr | 214.85 | |
Dec2024 | ₹4 Cr | -62.34 | |
Sep2024 | ₹11 Cr | 4.97 | |
Jun2024 | ₹10 Cr | -25.10 | |
Mar2024 | ₹13 Cr | -1.42 | |
Dec2023 | ₹14 Cr | 26.90 | |
Sep2023 | ₹11 Cr | 21.76 | |
Jun2023 | ₹9 Cr | - |
Operating Margins | |
---|---|
Q-o-Q | 202.57 % |
Y-o-Y | -26.88 % |
Quarters | Operating Margin% | % Change | |
---|---|---|---|
Mar2025 | 16.46% | 202.57 | |
Dec2024 | 5.44% | -60.23 | |
Sep2024 | 13.68% | -11.00 | |
Jun2024 | 15.37% | -31.72 | |
Mar2024 | 22.51% | 0.18 | |
Dec2023 | 22.47% | 14.23 | |
Sep2023 | 19.67% | 46.79 | |
Jun2023 | 13.4% | - |
BALAXI PHARMACEUTICALS Quarterly Profit After Tax
Profit After Tax(PAT) | |
---|---|
Q-o-Q | 61.10 % |
Y-o-Y | -20.99 % |
Quarters | Profit After Tax | % Change | |
---|---|---|---|
Mar2025 | ₹9 Cr | 61.10 | |
Dec2024 | ₹5 Cr | 16.87 | |
Sep2024 | ₹5 Cr | -29.20 | |
Jun2024 | ₹6 Cr | -40.73 | |
Mar2024 | ₹11 Cr | -19.57 | |
Dec2023 | ₹14 Cr | -5.78 | |
Sep2023 | ₹14 Cr | Positive | |
Jun2023 | ₹-41 Cr | - |
PAT Margins | |
---|---|
Q-o-Q | 54.78 % |
Y-o-Y | -37.99 % |
Quarters | PAT Margin(%) | % Change | |
---|---|---|---|
Mar2025 | 11.33 % | 54.78 | |
Dec2024 | 7.32 % | 23.44 | |
Sep2024 | 5.93 % | -39.92 | |
Jun2024 | 9.87 % | -45.98 | |
Mar2024 | 18.27 % | -18.29 | |
Dec2023 | 22.36 % | -15.21 | |
Sep2023 | 26.37 % | Positive | |
Jun2023 | -62.68 % | - |
BALAXI PHARMACEUTICALS Quarterly Earnings Per Share (EPS)
EPS | |
---|---|
Q-o-Q | 60.82 % |
Y-o-Y | -84.45 % |
Quarters | EPS | % Change | |
---|---|---|---|
Mar2025 | ₹1.56 | 60.82 | |
Dec2024 | ₹0.97 | 16.87 | |
Sep2024 | ₹0.83 | -29.06 | |
Jun2024 | ₹1.17 | -88.33 | |
Mar2024 | ₹10.03 | 277.07 | |
Dec2023 | ₹2.66 | -5.67 | |
Sep2023 | ₹2.82 | Positive | |
Jun2023 | ₹-8.08 | - |
You may also like the below Video Courses
ADANI ENTERPRISES LTD vs REDINGTON LTD vs MMTC LTD
HONASA CONSUMER LTD vs LLOYDS ENTERPRISES LTD vs ENTERO HEALTHCARE SOLUTIONS LTD